Initial intravitreal injection of high-dose ganciclovir for cytomegalovirus retinitis in HIV-negative patients

Zhuyun Qian†, Haili Li†, Yong Tao* and Wensheng Li†,4*

Abstract

Background: The purpose of this study is to examine the clinical outcomes achieved by using initial high-dose intravitreal ganciclovir injections to treat cytomegalovirus retinitis in patients without human immunodeficiency virus (HIV) infection.

Methods: Twenty-four eyes (24 patients) with cytomegalovirus retinitis received multiple intravitreal injections of ganciclovir in weekly intervals. A higher dose (6 mg) of ganciclovir was applied at the first intravitreal injection, and a lower dose was used for maintenance. Anterior aqueous humour was obtained before each injection. The best-corrected visual acuity and cytomegalovirus loads in the anterior aqueous humour were measured.

Results: The mean cytomegalovirus DNA load in aqueous humour decreased significantly from $(2.59 \pm 2.28) \times 10^5$ copies/mL at baseline to $(1 \pm 1.76) \times 10^4$ copies/mL one month later. The aqueous cytomegalovirus DNA load was negative in 17 eyes (70.8%) one month later. No obvious improvement of best-corrected visual acuity was found during the treatment. A positive correlation was proven between initial cytomegalovirus DNA titers in aqueous humour and the total number of intravitreal injections of ganciclovir, as well as between the baseline and final best-corrected visual acuities. No severe complications developed.

Conclusions: An initial high dose of ganciclovir (6 mg) and continuous intravitreal injections of ganciclovir could significantly decrease the cytomegalovirus load in HIV-negative patients with cytomegalovirus retinitis.

Trial registration: http://clinicaltrials.gov, NCT03598452, retrospectively registered on 24 July 2018.

Keywords: Cytomegalovirus retinitis, High-dose, Ganciclovir, Intravitreal injection, Aqueous humour

Cytomegalovirus (CMV) infection is common in the general population [1]. Nearly 60% of individuals over the age of 60 and more than 80% of those over the age of 80 exhibit seropositivity [2]. CMV infection remains asymptomatic in people with healthy immune systems, but in immunocompromised individuals (such as those with acquired immunodeficiency syndrome [AIDS], pharmacologic immunosuppression after organ grafting or hematologic malignancy, etc), it is a major cause of morbidity and mortality.

Active intraocular CMV infection leads to severe retinal destruction and poor prognosis if left untreated. CMV retinitis (CMVR) is classically associated with AIDS, but reports of CMVR in HIV-negative populations continue to increase due to the development of modern immunosuppressive therapies and improved survival rates [3, 4].

Diagnosis of CMVR is based on clinical symptoms and confirmed by the detection of CMV in an aqueous or vitreous samples by polymerase chain reaction (PCR) [5]. The first-line treatment of CMVR includes the systematic and topical use of ganciclovir. Foscarnet is considered in cases in which ganciclovir is intolerable or ineffective. Intravitreal antiviral drug delivery was used...
as the first-line treatment in several studies in which systematic injection had been ruled out [6–8]. The reported dose of intravitreal injections of ganciclovir (IVG) varied from 200 μg/0.1 mL to 5 mg/0.1 mL in patients with AIDS [9]. Our previous work showed the safety and the efficacy of 1 mg IVG in HIV-negative patients suffering from CMVR; the percentage of eyes in which CMV could not be detected rose with each consecutive injection. We proposed that a higher dose of ganciclovir in the first injection followed by lower maintenance doses would indicate a better result [10]. Therefore, this study was performed to evaluate the safety and the potential therapeutic effect of the initial high-dose IVG for CMVR in HIV-negative patients.

**Methods**

In the last four years, 26 HIV-negative patients were diagnosed with CMVR through ophthalmological examination and positive CMV DNA in aqueous humour by real-time PCR in department of ophthalmology, Beijing Chaoyang Hospital. All patients were identified using electronic medical records. Two of those patients had diabetic retinopathy and glaucoma and were excluded from this study. So, this clinical interventional case-series included 24 continuous patients with CMVR, which was consecutively treated by intravitreal injections of ganciclovir.

Among all studied patients, nine had bilateral ocular disease. To avoid the non-independence of eyes from the same person, data were collected in a randomly selected unilateral eye from each patient. The off-label use of the drug and its potential risks and benefits were discussed in detail with all patients, who then signed formal consents. The study was conducted in accordance with the Declaration of Helsinki. Institutional review board approval was obtained.

The initial dose was 6 mg/0.1 mL of ganciclovir; it was reduced to 4.5 mg/0.1 mL in the second injection, and 3 mg/0.1 mL of IVG was used as a maintenance dose. The injections were stopped at the discretion of the treating doctor based on CMV titers and an assessment of clinical efficacy and/or futility. The injection method was the same as we described in our previous reports [10]. Before each injection, 50 μL of anterior aqueous humour was obtained through paracentesis at seven o’clock, and real-time PCR was applied immediately to detect the load of aqueous CMV DNA level. In cases in which CMV DNA titer rose remarkably and retinal lesions aggravated after IVG, ganciclovir was regarded to be ineffective and was replaced by foscarnet. The interval between repeated injections was one week. No patients received systemic anti-viral treatment.

All patients underwent a detailed ophthalmological examination at each visit, including BCVA (best corrected visual acuity), applanation tonometry, biomicroscopy of anterior segment and funduscopy. BCVA was measured using a decimal chart and was converted into LogMAR for computing purposes; a value of 2.6 LogMAR units was assigned for visual acuity of count fingers, 2.7 LogMAR units for hand movement, 2.8 LogMAR units for light perception and 2.9 LogMAR units for no light perception [11]. Fundoscopy was used to evaluate the extent of involvement at the time of diagnosis (0°–90°, 90°–180° and 180°–360°). The amount of CMV DNA load in aqueous humour, the total number of injections and the occurrence of complications were recorded in detail. Recurrence of CMVR was defined as the presence of new lesions after the initial retinitis had been resolved and was inactive. The occurrence of IVG-related complications was also recorded to evaluate the safety of the treatment.

Statistical analyses were carried out using SPSS software for Windows (version 22.0; IBM-SPSS, Chicago, IL, USA). The Mann-Whitney U test was used to compare the initial CMV loads between unilateral and bilateral CMVR. BCVA and CMV DNA loads at the baseline and the one-month visit were compared using the Wilcoxon signed-rank test. In patients with negative CMV titers after IVG, the relationship between the total number of IVG and the initial CMV DNA titers in aqueous humour was calculated using regression analysis, which was also used to calculate the relationship between baseline BCVA and final BCVA. The Kruskal–Wallis test was used to explore the relationship between the initial CMV titer and the retinal extent of CMV. P-values represented results for two-sided tests, with values less than 0.05 considered statistically significant.

**Results**

The study cohort consisted of 24 patients (12 males and 12 females; 24 eyes total) with a mean age of 29.08 ± 14.16 years (range: 7–59 years). Among all included patients, 21 received hematopoietic stem cell transplantation therapy, while another 2 underwent chemotherapy due to the presence of a hematologic disease and 1 received thymectomy. Nine patients had bilateral disease. The mean CMV load in aqueous humour was (9.61 ± 17.67) × 10^4 copies/mL in unilateral CMVR and (7.89 ± 10.51) × 10^5 copies/mL in bilateral CMVR. No significant difference was found between the viral loads of the two groups (P = 0.817, Mann-Whitney U). The median follow-up time was 15 months (range: 3–42 months). The mean time-span from the beginning of the treatment to the retinitis quiescence was 3.74 ± 1.39 weeks (range: 1–7 weeks). No patient was lost in follow-up during the treatment except one patient died during the treatment. Table 1 lists the characteristics of the studied patients.
The mean load of CMV in aqueous humour at baseline was \((2.59 \pm 2.28) \times 10^5\) copies/mL, but it decreased significantly to \((1 \pm 1.76) \times 10^4\) copies/mL after four IVG \((P = 0.000,\) Wilcoxon signed-rank; Fig. 1). The mean number of IVGs was \(3.46 \pm 1.06\) (range: \(1–5\) injections).

The CMV DNA titer was tested negative in \(6\) eyes (\(25\%\)) after \(2\) injections, in \(11\) eyes (\(45.8\%\)) after \(3\) injections and in \(17\) eyes (\(70.8\%\)) after \(4\) injections. The mean Log-MAR BCVA was \(0.87 \pm 0.86\) (range: \(0–2.8\)) at baseline and \(0.70 \pm 0.79\) (range: \(0–2.9\)) at the one-month visit, which indicated no obvious improvement \((P = 0.112,\) Wilcoxon signed-rank). The retinal extent of CMVR was ‘\(0°–90°\)’ in \(9\) eyes, ‘\(90°–180°\)’ in \(6\) eyes and ‘\(180°–360°\)’ in \(9\) eyes. The initial aqueous CMV DNA load was not statistically correlated with the CMVR extent \((P = 0.098,\) Kruskal–Wallis).

Regression analysis revealed a positive correlation between initial CMV DNA titers in aqueous humour and the total number of IVG (Fig. 2a; \(R^2 = 0.772,\ P = 0.000)\), as well as between baseline BCVA and final BCVA (Fig. 2b; \(R^2 = 0.762, P = 0.000)\). Three eyes (\(12.5\%\)) suffered recurrence of CMVR during the follow-up period. New lesions appeared in fundus examination, and CMV was redetected in aqueous humour several months (range: \(2–6\) months) after the regression of primary retinal lesions. In these patients, \(3\) mg/\(0.1\) mL of IVG was restarted. CMVR relapsed in three eyes (\(12.5\%\)), in which we detected a rise of CMV DNA load in aqueous humour and enlarged retinal lesions in fundus examination after several IVG. Intravitreal foscarnet of \(2.4\) mg was used as a substitute (Fig. 3). IVG was stopped in one eye because there was no light perception after three injections, while in another eye, IVG was stopped after five injections due to vitrectomy and silicone oil tamponade. One patient died due to cytomegaloviral pneumonia one month after the CMV load turned negative. No retinal detachment due to intravitreal injection or endophthalmitis occurred during the treatment. No drug toxicity reaction was observed during the treatment.

**Discussion**

Ganciclovir interferes with DNA polymerase, resulting in inhibition of viral replication. Previous studies have proven the efficacy of systematic ganciclovir in the treatment of CMVR in both HIV-positive and HIV-negative patients [12–15]. Vishnevskia-Dai V et al. proposed a repeated intravitreal use of ganciclovir and/or foscarnet in cases of macular or optic disc-threatening disease [16]. Side effects of systematic ganciclovir include renal failure, neutropenia or thrombocytopenia, which are commonly experienced in patients with myelosuppression [10, 17]. However, intravitreal use of ganciclovir has

---

**Table 1** Baseline Characteristics of Involved Patients

| Characteristics                  | Patients (n = 24) |
|----------------------------------|------------------|
| Age (year), mean ± SD (range)    | 29.08 ± 14.16 (7–59) |
| Gender, n (%)                   |                  |
| Male                             | 12 (50)          |
| Female                           | 12 (50)          |
| Eyes, n (%)                      |                  |
| Unilateral                       | 15 (62.5)        |
| Bilateral                        | 9 (37.5)         |
| Primary disease, n (%)           |                  |
| Hematologic disease              | 23 (95.8)        |
| Post HSCT                        | 21 (87.5)        |
| Chemotherapy                     | 2 (8.3)          |
| Thymectomy                       | 1 (4.2)          |

SD, standard deviation; HSCT, hematopoietic stem cell transplantation therapy

---

![Slide](image.png)

**Fig. 1** CMV DNA titer in aqueous humour of patients with CMVR during first four IVG once a week. CMV load decreased continuously during the procedure.
a low systemic exposure. Direct intraocular use also has the advantage of achieving therapeutic levels by circumventing the inefficiency of ganciclovir in crossing the blood-retina barrier [10]. In the previous study, we indicated that the major disadvantage of IVG was its little benefit for the fellow eye with no virus infection, but now we had impression that the progression of lesions in the fellow eye could be controlled well with close follow-up and timely treatment.

Compared to our previous study, the major difference in this treatment was the dose of intravitreal ganciclovir. We previously used 1 mg/time ganciclovir for each injection; in this study, the first injection dose was increased to 6 mg, followed by lower doses of 4.5 mg and 3 mg. Our present study suggests that this treatment regimen could also significantly reduced the CMV DNA titers in CMV-infected eyes. However, the percentage of patients with CMV turning negative after each injection did not...
increase in this study. On the contrary, in our present study, 25% of patients were CMV-negative after two injections, which was lower than what we reported in the previous study (47.8%) [10]. This difference could be attributed to the limited number of patients in both studies or the individual differences of sensitivity to ganciclovir. No significant improvement in BCVA was found in involved patients, even with the decrease of CMV in aqueous humour. The result was the same as in our previous study in which 1 mg IVG had been used as the treatment regimen. However, the final BCVA proved to be positively correlated with the baseline BCVA. We had the impression that eyes with good initial visual acuity (LogMAR BCVA less than 0.3) commonly had stable or improved BCVA at the final visit. According to our observations, most eyes with poor initial visual acuity had macular involvement (the macula is mainly responsible for photopic vision). We presume that the damage of photoreceptors by CMV infection is irreversible and irreparable, even if the lesion becomes inactive following the decrease of CMV DNA titers.

Joens et al. reported a mean number of 10 injections (range: 2–22) of ganciclovir with a dose of 2 mg/time, while in the study of Lu et al., the results were similar [18, 19]. In our study, the mean number of IVG was 3.46 ± 1.06, which was much less than in the above-mentioned studies. This discrepancy could be attributed to the higher dose of intravitreal ganciclovir in our study or the timely change to foscarnet when ganciclovir was ineffective in decreasing CMV DNA titer. We also found a strong relationship between the initial CMV DNA titers and the total number of IVG, which may be a predictive indicator of the treatment time spent in the following treatment.

In the present study, three eyes (12.5%) suffered recurrence of CMVR, which was lower than in the study of Lu et al [19]. Several patients with recurred CMVR provided a history of ‘staying up late’ or ‘overworking,’ from which we speculated that reduced immune function played a role in the reactivation of intraocular CMV. In the other three eyes, CMV DNA titers rose after several IVG, continuous lesion enlargement was observed and ganciclovir was replaced by intravitreal injections of foscarnet. A possible reason for the relapse was the non-response of the virus to ganciclovir, especially in our case because the initial dose of IVG was high. In these cases, the timely change to other antiviral agents is essential to prevent continuous damage to the retina by CMV.

Choopong et al. reported a case of sudden crystallization in vitreous cavity after 4 mg/0.04 mL ganciclovir, which caused optic atrophy [20]. It was speculated that high drug concentrations introduced in the eyeball globe lead to the sudden change of pH in the vitreous humour, which might cause crystallization of ganciclovir. The dose of ganciclovir we used was higher than as reported above, but the concentration was lower to prevent such an accident.

In sum, patients treated with weekly intravitreal ganciclovir injections (6 mg initially, then 4.5 mg, then 3 mg until cessation of therapy) experienced a significant reduction in anterior chamber CMV load. The mean total number of injections was less than that of previous studies. A positive correlation was proven between initial CMV DNA titers in aqueous humour and the total number of IVG, as well as between baseline BCVA and final BCVA.

Our study had certain inherent limitations due to its retrospective design. It also did not include a control group, so we cannot form any conclusions regarding the relative efficacy of this treatment over any other treatment. The sample size of this study was also relatively small, which may limit the statistical strength of the findings. Therefore, further studies with prospective, controlled design and a larger number of included patients are needed to confirm our conclusion.

Abbreviations
BCVA: Best-corrected visual acuity; CMV: Cytomegalovirus; CMVR: CMV retinitis; IVG: Intravitreal injections of ganciclovir; PCR: Polymerase chain reaction

Acknowledgements
Not applicable.

Funding
This work was supported by the 1351 talent training program (No. CYXX-2017-21), the Fok Ying-Tong Education Foundation (No. 141038), the Science Research Foundation of Aier Eye Hospital Group (No. AFM1701D3) and the Technology Innovation Program of Hunan Province (No. 2017SK50901). These funding bodies play no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
ZYQ analysed the data and drafted the manuscript. HLL collected the data and revised the manuscript. WSL performed the study and revised the manuscript. YT designed and performed the study, collected the data and gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The ethics committees of the Beijing Capital Medical University and Beijing Chaoyang Hospital approved this study, and informed consent was obtained from all patients.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
*1Shanghai Aier Eye Hospital, Shanghai, China, No. 1286, Hongqiao Road, Changning District, Shanghai 200050, China. 2Department of Ophthalmology,
References

1. Teoh SC, Wang PX, Wong EP. The epidemiology and incidence of cytomegalovirus retinitis in the HIV population in Singapore over 6 years. Invest Ophthalmol Vis Sci. 2012;53:7546–52.

2. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Prevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43:1143–51.

3. Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthamol. 2012;119:1892–8.

4. Pathanapitoon K, Tesavibul N, Choopong P, Boonsopon S, Kongsy P, Ausayakhun S, et al. Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without human immunodeficiency virus infection. JAMA Ophthalmol. 2013;131:638–45.

5. Fox GM, Crouse CA, Chuang EL, Pflugfelder SC, Cleary TJ, Nelson SJ, et al. Detection of herpesvirus DNA in vitreous and aqueous specimens by the polymerase chain reaction. Arch Ophthalmol. 1991;109:266–71.

6. Langner-Wegscheider BJ, ten Dam-van Loon N, Mura M, Faridpooya K, de Smet MD. Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis. Can J Ophthalmol. 2010;45:157–60.

7. Mota A, Breda J, Silva K, Magalhaes A, Falcão-Reis F. Cytomegalovirus retinitis in an immunocompromised infant: a case report and review of the literature. Case Report Ophthalmol. 2011;2:238–42.

8. Singh R, Singh R, Trehan A, Jain R, Bhalekar S. Cytomegalovirus retinitis in an ALL child on exclusive chemotherapy treated successfully with intravitreal ganciclovir alone. J Pediatr Hematol Oncol. 201235:e118–9.

9. Choopong P, Vittaworn K, Konlakij D, Thongsuwan S, Pitukshun A, Tesavibul N. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis. BMC Infect Dis. 2016;16(16):164.

10. Miao H, Tao Y, Jiang Y-R, Li X-X. Multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis after stem-cell transplantation. Graefes Arch Clin Exp Ophthalmol. 2013;251:1829–33.

11. Grover S, Fishman GA, Anderson RJ, Tozatti MS, Heckenlively JR, Weleber RG, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106:1780–5.

12. Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol. 2004;138:338–46.

13. Eid AI, Bakri SJ, Kijpittayarit S, Razonable RR. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis. 2008;10:13–8.

14. Martin DF, Sierra-Madero J, Walmsley S, Wiltz RA, Macey K, Georgiou P, et al. Valganciclovir study group. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119–26.

15. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir Res. 2006;71(2–3):154–63.

16. Vishnevskia-Dai V, Shapira Y, Rahav G, Shimon A, Somech R, Moisseiev J. Cytomegalovirus retinitis in HIV-negative patients: a practical management approach. Ophthalmol. 2015;122(4):866–8.

17. Song WK, Min YH, Kim YR, Lee SC. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab. Ophthalmology. 2008;115:1766–70.

18. Jeon S, Lee WK. Cytomegalovirus retinitis in a human immunodeficiency virus-negative cohort: long-term management and complications. Ocul Immunol Inflamm. 2015;23(5):392–9.

19. Liu LP, Fan MC, Lau JK, Chan TS, Kwong YL, Wong JY. Long-term follow-up of cytomegalovirus retinitis in non-HIV immunocompromised patients: clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53.

20. Choopong P, Tesavibul N, Rodnanant N. Crystallization after intravitreal ganciclovir injection. Clin Ophthalmol. 2010;4(6):709–11.